Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001050625 | SCV001214743 | likely benign | X-linked severe combined immunodeficiency | 2024-01-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002553227 | SCV003627652 | uncertain significance | Inborn genetic diseases | 2022-06-30 | criteria provided, single submitter | clinical testing | The c.37T>C (p.F13L) alteration is located in exon 1 (coding exon 1) of the IL2RG gene. This alteration results from a T to C substitution at nucleotide position 37, causing the phenylalanine (F) at amino acid position 13 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003405253 | SCV004113750 | uncertain significance | IL2RG-related disorder | 2023-02-20 | criteria provided, single submitter | clinical testing | The IL2RG c.37T>C variant is predicted to result in the amino acid substitution p.Phe13Leu. To our knowledge, this variant has not been reported in the literature. This variant is reported in a male (hemizygous individual) in gnomAD (http://gnomad.broadinstitute.org/variant/X-70331353-A-G). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |